Huaren Pharmaceutical(SZ:300110) Xin Lang Cai Jing·2025-10-30 02:26Core Insights - Huarun Pharmaceutical (300110.SZ) reported a total revenue of 976 million yuan for Q3 2025, ranking 59th among disclosed peers, which represents a decrease of 97.35 million yuan or 9.07% year-on-year [1] - The net profit attributable to shareholders was 54.58 million yuan, ranking 72nd among peers, down by 40.95 million yuan or 42.87% compared to the same period last year [1] - The net cash inflow from operating activities was 257 million yuan, ranking 38th among peers, a decrease of 28.76 million yuan or 10.08% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 58.02%, ranking 108th among peers, a decrease of 0.72 percentage points from the previous quarter, but an increase of 16.25 percentage points year-on-year [3] - The latest gross profit margin is 34.15%, ranking 86th among peers, down by 3.59 percentage points from the previous quarter and down by 1.95 percentage points year-on-year [3] - The latest return on equity (ROE) is 4.03%, ranking 65th among peers, an increase of 0.57 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.05 yuan, ranking 84th among peers, a decrease of 0.03 yuan or 42.82% year-on-year [3] - The latest total asset turnover ratio is 0.29 times, ranking 64th among peers, an increase of 0.07 times or 33.75% year-on-year [3] - The latest inventory turnover ratio is 2.25 times, ranking 36th among peers, an increase of 0.13 times or 5.94% year-on-year [3] Shareholder Information - The number of shareholders is 40,600, with the top ten shareholders holding a total of 501 million shares, accounting for 42.34% of the total share capital [3] - The largest shareholder is Xi'an Qujiang Tianshou Health Investment Partnership (Limited Partnership) with a holding of 20.01% [3]